Pre-approval Single-patient Expanded Access for Elranatamab (PF-06863135)

Outpatient and Intermittent Dosing of Elranatamab in Relapsed/Refractory Multiple Myeloma

NCT06421675 ·Status: RECRUITING ·Phase: PHASE2

Pre-Approval Access Single Patient Request for Talquetamab in Relapsed or Refractory Multiple Myeloma

NCT05503550 ·Status: NO_LONGER_AVAILABLE

Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant

NCT05317416 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3

Pre-approval Access Single Patient Request for Teclistamab (JNJ-64007957)

NCT05161598 ·Status: NO_LONGER_AVAILABLE

A Study to Compare the Effects of Elranatamab (PF 06863135) Versus Standard of Care (SOC) in Patients With Multiple Myeloma (MM) in Germany and US

NCT06504524 ·Status: COMPLETED

Non Interventional Study to Investigate the Safety and Effectiveness in Patients With Relapsed and Refractory Multiple Myeloma Treated With Elranatamab Under the Actual Use.

NCT06479954 ·Status: ACTIVE_NOT_RECRUITING

A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments

NCT05020236 ·Status: RECRUITING ·Phase: PHASE3

ELISA in Relapsed/Refractory MM

NCT06832865 ·Status: RECRUITING ·Phase: PHASE2

Self-administration of Subcutaneous Elranatamab in the Patients' Homes.

NCT06015542 ·Status: RECRUITING ·Phase: PHASE2

A Study of Elranatamab (PF-06863135) in Chinese Participants With Refractory Multiple Myeloma.

NCT05228470 ·Status: COMPLETED ·Phase: PHASE2

PF-06863135 As Single Agent And In Combination With Immunomodulatory Agents In Relapse/Refractory Multiple Myeloma

NCT03269136 ·Status: COMPLETED ·Phase: PHASE1

Pre-Approval Access Program for Talquetamab in Relapsed or Refractory Multiple Myeloma

NCT05757973 ·Status: APPROVED_FOR_MARKETING

Measurable Residual Disease-Guided Post-Transplant Elranatamab Maintenance

NCT06483100 ·Status: RECRUITING ·Phase: PHASE2

Teclistamab Expanded Access Treatment Protocol for Relapsed or Refractory Multiple Myeloma Patients

NCT05463939 ·Status: APPROVED_FOR_MARKETING

Elranatamab/Lenalidomide Consolidation and/or Elranatamab Maintenance Versus Standard of Care After D-VRd Induction in Transplant-eligible NDMM Patients

NCT06918002 ·Status: RECRUITING ·Phase: PHASE3

A Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Mezigdomide in Combination With Elranatamab in Participants With Relapsed and/or Refractory Multiple Myeloma

NCT06988488 ·Status: RECRUITING ·Phase: PHASE1/PHASE2

Elranatamab in Patients With Relapsed or Refractory AL Amyloidosis

NCT06569147 ·Status: RECRUITING ·Phase: PHASE1/PHASE2

Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma

NCT03361748 ·Status: COMPLETED ·Phase: PHASE2

ERd Combination Treatment in Newly Diagnosed Multiple Myeloma

NCT06997081 ·Status: RECRUITING ·Phase: PHASE2

A Study to Learn About the Effects of the Combination of Elranatamab (PF-06863135) and Iberdomide in Patients With Relapsed or Refractory Multiple Myeloma (MagnetisMM-30)

NCT06215118 ·Status: RECRUITING ·Phase: PHASE1

Expanded Access Treatment Protocol CA204-143

NCT02368301 ·Status: NO_LONGER_AVAILABLE

Expanded Access to Elotuzumab (Empliciti) for Multiple Myeloma

NCT03126617 ·Status: NO_LONGER_AVAILABLE

MagnetisMM-3: Study Of Elranatamab (PF-06863135) Monotherapy in Participants With Multiple Myeloma Who Are Refractory to at Least One PI, One IMiD and One Anti-CD38 mAb

NCT04649359 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

Expanded Access Single Named Patient Program With Elotuzumab (BMS-901608) for the Treatment of Patient R-A With Relapsed/Refractory Multiple Myeloma

NCT02541643 ·Status: NO_LONGER_AVAILABLE

A Phase 1b/2, Dose-Escalation Study of Elotuzumab (Humanized Anti-CS1 Monoclonal IgG1 Antibody) in Relapsed Multiple Myeloma

NCT00742560 ·Status: COMPLETED ·Phase: PHASE2